Back to results
US 6,685,933 B1Granted
Interferon α hybrids
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsKathryn C. Zoon, Renqiu Hu, Joseph B. Beiksz, Mark P. Hayes
Life of this patent
Estimating the term…
Abstract
Hybrid human interferon-α polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these peptides, and the use of these polypeptides to treat viral disease and regulate cell growth are also provided.
Claims11
A purified hybrid interferon-α polypeptide, comprising
- a first amino acid sequence consisting of residues 1-75 of interferon-α2c;
- a second amino acid sequence consisting of residues 76-81 of interferon-α2c or residues 76-81 of interferon-α21a;
- a third amino acid sequence consisting of the sequence LDKFXTELXQQLND or the sequence LEKFXTELXQQLND, wherein X is any amino acid residue;
- and
- a fourth amino acid sequence consisting of residues 96-166 of interferon-α21a;
- wherein the C-terminal residue of the first amino acid sequence is fused to the N-terminal residue of the second amino acid sequence;
- and the C-terminal residue of the second amino acid sequence is fused to the N-terminal residue of the third amino acid sequence;
- and the C-terminal residue of the third amino acid sequence is fused to the N-terminal residue of the fourth amino acid sequence;
- and
- wherein the hybrid interferon-α polypeptide has interferon-α protein biological activity.
7 more elements
A cell transformed with the recombinant vector according to claim 9.
Dependencies are inferred from the claim text.